The FRAX® tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women with breast cancer who were treated with aromatase inhibitors, which cause accelerated bone loss, when combined with bone mineral density measurements.
The FRAX® tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women with breast cancer who were treated with aromatase inhibitors, which cause accelerated bone loss, when combined with bone mineral density measurements.
However, the results also question the practice of considering aromatase inhibitors a “secondary cause of osteoporosis” when the FRAX® tool is used without bone mineral density, because this can lead to overestimation of fracture risk. Nonetheless, it is very important to determine fracture risk in women receiving aromatase inhibitor therapy who will most likely experience bone loss during treatment.
“We hope that our data will help to inform clinical guidelines regarding fracture risk assessment in women with breast cancer, and the incorporation of FRAX® in management algorithms of those receiving aromatase inhibitors,” said lead author Dr. William D. Leslie, of the University of Manitoba, in Canada.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.3726
About Journal
The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale “-omics” approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.
About Wiley
Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.
Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com